BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
Plexigen
Plexigen developed a proprietary 3-D biochip designed to significantly enhance the capacity, efficiency, accuracy and automation of gene screening.
Plexigen
Cary, NC
